Skip to Content

ExonHit presents promising first patient results for EHT 0202, its Alzheimer's candidate drug

ExonHit presents promising first patient results for EHT 0202, its Alzheimer’s candidate drug

* Primary endpoints: Good safety and tolerability data supports moving into Phase IIb * Secondary exploratory endpoints: A trend for efficacy on cognition was observed on ADAS-Cog scores and in ApoE4 positive population * ExonHit seeking a partner for further development & commercialization of EHT 0202

Paris,  September 14, 2009 – Top-line Phase IIa clinical data released today demonstrate that EHT 0202, ExonHit’s lead candidate for the treatment of Alzheimer’s disease, is safe and generally well tolerated in patients and that it could potentially enhance cognition in Alzheimer’s disease patients. These first EHT 0202 results in patients were presented today in Florence, Italy, at the 13th Congress of the European Federation of Neurological Societies (1). Further study details will be disclosed at the 2nd Conference of Clinical Trials on Alzheimer Disease in Las Vegas, at the end of October.

“EHT 0202 has an original mechanism of action with potential disease-modifying and symptomatic properties. The Phase IIa safety results and the potential efficacy signals observed in Alzheimer patients support advancing EHT 0202 into later stage clinical development to collect further evidence of safety and efficacy in a larger number of patients and over a longer time period,” stated Professor Bruno Vellas, M.D., the principal investigator. “There is a high unmet need for new Alzheimer treatments with procognitive and neuroprotective properties.”

“We are very happy about these promising findings as EHT 0202 could become a new approach to the treatment of Alzheimer’s disease,” commented Dr. Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics. “ExonHit will now actively look for a partner to ensure rapid clinical development and commercialization of EHT 0202.”


Caroline Carmagnol ALIZE RP + 33 6 64 18 99 59



Posted: September 2009